Daniela Sanchez Basseres in research grants and scholarships supported by FAPESP.
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Pancreatic ductal adenocarcinoma (PDAC), which represents over 90% of all pancreatic tumors, is a highly aggressive and lethal disease with a 5-year overall survival of less than 10%. This dismal prognosis is due, among other factors, to the early and extremely aggressive metastatic spread of this type of tumor coupled with resistance to chemotherapy. One of the most important hallmarks o…
The most common genetic abnormalities found in lung cancer are activating mutations in the KRAS oncogene. Even though these mutations have been causally linked to the oncogenic process, therapies targeted to oncogenic RAS have sofar failed. Therefore, in order to select better targets for lung cancer therapy, one will need to identify key cancer-relevant KRAS downstream pathways involved …
Pancreatic ductal adenocarcinoma (PDAC) is an extremely lethal disease and accounts for more than 90% of pancreas tumors. The high lethality is due, in part, to the tumor intrinsic or acquired chemotherapeutic resistance and to the high metastatic potential of this type of cancer, with metastasis being an early event in the PDAC evolution and present in 50% of diagnosed patients. The tumo…
Lung cancer induced by oncogenic mutations of the KRAS GTPase is a very frequent disease, for which there are currently no effective therapies. Although these mutations are closely linked to oncogenesis, different approaches to inhibit RAS proteins directly have previously failed. Therefore, for better therapeutic targets for lung cancer to become available, it is necessary to identify th…
Activating mutations in KRAS are very frequent in Pancreatic Ductal Adenocarcinomas (PDACs), but different approaches to directly target Ras for therapy failed in clinical trials. An alternative route for blocking RAS-driven oncogenic pathways is to target downstream effectors of RAS involved in promoting the oncogenic phenotype. Long non-coding RNAs (lncRNAs) regulate gene expression thr…
Lung cancer is the leading cause of cancer deaths worldwide. The most frequent genetic changes found in lung cancer are driver mutations in the KRAS proto-oncogene. Even though KRAS mutations have been causally linked to the oncogenic process, therapies targeted to oncogenic RAS have failed in clinical trials. Therefore, in order to select better targets for lung cancer therapy, it will b…
(Only some records are available in English at this moment)
Lung cancer induced by oncogenic mutations of the KRAS GTPase is a very frequent disease, for which there are currently no effective therapies. Although these mutations are closely linked to oncogenesis, small molecules to inhibit RAS proteins effectively in the clinic still do not exist. Therefore, for better therapeutic targets for lung cancer to become available, it is necessary to ide…
| 5 / 3 | Completed research grants |
| 1 / 1 | Ongoing scholarships in Brazil |
| 14 / 10 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 21 / 15 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID